Adamis Pharmaceuticals Corporation   Report issue

For profit Phase 2 Phase 3
Founded: San Diego CA United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2011
NCT01436214
First Marketed Drug
2017
epinephrine (levophed)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Adamis Pharmaceutical Corporation | Adamis Pharmaceuticals Corporation | ADAMIS PHARMS CORP

Active Ingredients

Marketed Drugs (2)

epinephrine (levophed) (2017)

naloxone (narcan) (2021)

Drugs in Phase 3 Trials (3)

Key: Adamis Pharmaceuticals Corporation (2) Acquired (1)

beclomethasone (vanceril) (2 trials)

monolaurin (1 trial)

tempol (1 trial)

Drugs in Phase 2 Trials (1)

apc-100 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4